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Abstract
Background: Amyloid-β (Aβ) 42 has been implicated as the initiating molecule in the pathogenesis of Alzheimer’s
disease (AD); thus, therapeutic strategies that target Aβ42 are of great interest. γ-Secretase modulators (GSMs) are
small molecules that selectively decrease Aβ42. We have previously reported that many acidic steroids are GSMs
with potencies ranging in the low to mid micromolar concentration with 5β-cholanic acid being the most potent
steroid identified GSM with half maximal effective concentration (EC50) of 5.7 μM.
Results: We find that the endogenous cholesterol metabolite, 3β-hydroxy-5-cholestenoic acid (CA), is a steroid
GSM with enhanced potency (EC50 of 250 nM) relative to 5β-cholanic acid. CA i) is found in human plasma
at ~100-300 nM concentrations ii) has the typical acidic GSM signature of decreasing Aβ42 and increasing Aβ38
levels iii) is active in in vitro γ-secretase assay iv) is made in the brain. To test if CA acts as an endogenous
GSM, we used Cyp27a1 knockout (Cyp27a1−/−) and Cyp7b1 knockout (Cyp7b1−/−) mice to investigate if
manipulation of cholesterol metabolism pathways relevant to CA formation would affect brain Aβ42 levels. Our
data show that Cyp27a1−/− had increased brain Aβ42, whereas Cyp7b1−/− mice had decreased brain Aβ42
levels; however, peripheral dosing of up to 100 mg/kg CA did not affect brain Aβ levels. Structure-activity relationship
(SAR) studies with multiple known and novel CA analogs studies failed to reveal CA analogs with increased potency.
Conclusion: These data suggest that CA may act as an endogenous GSM within the brain. Although it is
conceptually attractive to try and increase the levels of CA in the brain for prevention of AD, our data suggest that
this will not be easily accomplished.
Keywords: Cholestenoic acid, γ-secretase modulator (GSM), Amyloid, Alzheimer disease, Cholesterol, Steroid, Bile
acid, Cytochrome P450
Background
Accumulation of aggregated amyloid β peptides (Aβ) in
the brain is proposed to be a key trigger in a complex
neuropathological cascade that leads to Alzheimer’s dis-
ease (AD). Aβ is produced from the amyloid precursor
protein (APP) through sequential proteolytic cleavages
[1]. APP is first cleaved by β-secretase to produce a
soluble APPβ and a membrane anchored APP carboxyl
terminal fragment (CTFβ). The CTFβ is then cleaved by
γ-secretase to produce extracellular Aβ peptides and
APP-intracellular domain (AICD) fragments. Notably, a
number of Aβ peptides are normally produced, with
Aβ40 being the most abundant species with minor spe-
cies including, but not limited to, Aβ37, 38, 39 and 42
routinely observed in most studies. These various spe-
cies are not produced by simple classic endoproteolysis
at multiple sites, but appear to arise from both variation
in the initial substrate cleavage site which produces
longer Aβs (i.e., Aβ48, Aβ49, and Aβ51) and the cognate
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AICD, which is then followed by multiple cycles of step-
wise, carboxyl-peptidase like cleavages, all of which are
mediated by γ-secretase. Although all Aβ peptides
normally produced appear to accumulate in the human
AD brain, the minor Aβ42 species is typically the most
prevalent form that accumulates in the brain parenchyma
[2, 3]. Additional lines of evidence further support the
concept Aβ42 is the most pathogenic isoform [4],
whereas Aβ40 may, under some circumstances, be a
protective isoform [5, 6]. Many early onset familial AD
(FAD) mutations linked with APP and Presenilin
(PSEN, the catalytic subunit of γ-secretase) increase
the relative levels of Aβ42 [7–10]. In vitro studies
show that Aβ1-42 has a much stronger tendency to
aggregate than Aβ1-40 [11]. In AD mouse model, Aβ42
plays a role as a seeding molecule for amyloid deposition
but Aβ40 [6] does not. In fact, Aβ40 appears to prevent
mice from amyloid deposition [5, 12]. Moreover, Aβx-42
is the earliest detectable Aβ isoform in the brain par-
enchyma [13–16]. The role of other shorter carboxyl-
terminal truncated species is at this point unclear,
though it is hypothesized that they may behave like
Aβ40 [5, 17]. Altogether, there is ample rationale that
decreasing the levels of Aβ42 could be a prophylactic
approach to prevent accumulation of Aβ and, thereby,
delay or prevent the development of AD.
There have been studies demonstrating that production
and processing of Aβ can be influenced by membrane
lipid composition [18–21]. In particular, membrane chol-
esterol appears to play an important role [18]. APP-CTFβ
and γ-secretase are found in lipid rafts, composed pri-
marily of cholesterol [18]. Further, it has been shown
that cholesterol directly binds to the APP-CTFβ sub-
strate [22, 23]. The interdependent interactions among
the three components (APP-CTFβ, γ-secretase, and chol-
esterol) are postulated to create the optimal microenvir-
onment for Aβ production. Indeed, it has been reported
that γ-secretase activity is largely dependent on the
amount of cholesterol, which affects Aβ production as
a result [18, 24] though others have not reproduced this
finding [25]. These observations suggest the potential for
modulating γ-secretase activity and thus altering the
overall Aβ levels or the ratios of Aβ isoforms produced
by steroid derivatives as cholesterol surrogates.
Previously, we have reported steroid carboxylic acid γ-
secretase modulators (GSMs) [26]. Numerous acidic ste-
roids decrease Aβ42 levels and increase Aβ38 levels
without changing total Aβ or Aβ40 levels [26]. Acidic
steroid GSMs have gross structural similarity to the
established-NSAID based GSMs in that a carboxylic acid
group, that is key for GSM activity, is attached by a car-
bon tether chain to a highly lipophilic core structure [26,
27]. 5β-Cholanic acid (ursocholanic acid) was the most
potent steroid GSM identified in our previous study with
an EC50 of 5.7 μM, but the endogenous bile acids, litho-
cholic acid and ursocholic acid, were also found to be
GSMs [26]. Mechanistically, GSMs decrease production
of Aβ42 selectively by promoting step-wise γ-secretase
cleavage and, thus, inherently increase shorter Aβ pep-
tides [28, 29]. Because γ-secretase cleavage activity partic-
ipates in a broad spectrum of cellular signaling
mechanisms (i.e., Notch-1) [30], indiscriminate inhibition
of γ-secretase activity has been essentially abandoned as a
therapeutic approach for AD due to debilitating side ef-
fects associated with target-based toxicity. In contrast,
GSMs do not alter overall γ-secretase activity, appear to
be relatively selective for APP, and are, therefore, thought
to be an intrinsically safe mechanistic approach to AD
therapy; however, it has been challenging to identify
GSMs that are potent, have sufficient brain penetrance,
and lack off-target toxicity.
Considering that GSMs derived from synthetic com-
pounds have toxicity issues that are not associated with
target-based toxicity, we have explored whether other
naturally occurring acidic steroids might have sufficient
potency to be therapeutically useful. An extended screen-
ing identified 3β-hydroxy-5-cholestenoic acid (CA) as a
highly potent GSM with an EC50 for Aβ42 lowering of
250 nM. As CA is produced endogenously during the
course of cholesterol elimination in many extrahepatic
organs including the brain [31, 32] and is present in
human plasma at concentrations near its EC50 for
GSM activity, we explored whether CA might function
endogenously as a GSM. Our results showed that
Cyp27a1−/− [33, 34] and Cyp7b1−/− [35] mice that
reduce or increase brain CA, respectively, resulted in
the predicted brain Aβ42 changes consistent with the
hypothesis that CA is an endogenous GSM. Peripheral
dosing of CA in wild type mice dramatically increased
plasma CA levels, but not brain Aβ levels, suggesting lim-
ited brain exposure of peripheral CA. Structure-activity
relationship (SAR) with multiple known and novel CA an-
alogs studies failed to reveal CA analogs with increased
potency. These studies show that though CA is a potent
GSM that may act within the brain to regulate Aβ42
levels, exogenous administration of CA is not likely
to be therapeutically useful for lowering Aβ42.
Results
CA is a potent GSM
Based on previous studies that showed a number of
acidic steroids are GSMs [26], we continued to test
other additional acidic steroids for GSM activity. These
studies revealed that the endogenous cholesterol me-
tabolite CA (Fig. 1a) had potent GSM activity. In cell-
based assays, the EC50 value for decreasing Aβ42 levels
was 250 nM and, consistent with other acidic steroid
GSMs, Aβ38 increased without alterations in total Aβ
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(Fig. 1b). CA’s GSM activity was further confirmed by
IP/MS analysis using the conditioned media produced
from CHO2B7 cells, which revealed selective lowering
of Aβ42 and increased Aβ38 (Fig. 1c). To assess whether
CA has a direct effect on γ-secretase, we performed in
vitro γ-secretase cleavage assays (Fig. 1d-f ). In these as-
says CA treatment decreased Aβ42 production by 51 %
without any significant changes in total Aβ levels when
the Aβ levels were compared to DMSO control (Fig. 1d).
Compound E (Cmpd E), a non-selective γ-secretase
inhibitor, decreased both Aβ42 (91 %) and total Aβ (77 %)
production significantly (Fig. 1d). These Aβ levels demon-
strate the initial Aβ levels in the assays. IP/MS Aβ and
AICD profiles from the in vitro assay are illustrated in
Fig. 1e and f, respectively. Again CA decreased Aβ42 and
increased Aβ38 (Fig. 1e) and, as noted with previous stud-
ies of GSMs, did not affect ε-site utilizations (AICD49-99
and AICD50-99) (Fig. 1f). Next, we utilized primary
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Fig. 1 γ-Secretase modulatory effect of CA. a Chemical structure of CA with EC50 and EC90 for decreasing Aβ42 is illustrated. b Dose response
curves of CA for Aβ42, Aβ38, and total Aβ in CHO-2B7 cells are shown. The Aβ levels in the conditioned media of the cells treated with CA at
nine dose points for 16 h were measured by Aβ specific sandwich ELISAs. Aβ42 (red line) levels increase with the concentration, whereas Aβ38
(green line) levels decrease with the concentration. Total Aβ (black line) levels did not show significant changes. c Aβ spectra are illustrated by
mass spectrometry after CA treatment at 3 μM in CHO-2B7 cells. Control refers to the conditioned media treated with DMSO in the cells, a solvent
for CA. CA treatment at 3 μM increased Aβ38 peak and decreased Aβ42 peak with no significant changes in Aβ40 peak compared to the DMSO
control. Identified Aβ peptides are indicated above the peaks. d In vitro γ-secretase assays show the direct effect of CA in γ-secretase modulation
analyzed by ELISAs. Cmpd E is an irreversible pan γ-secretase inhibitor, which limits γ-secretase activity at the starting time point of the assay. The
total γ-secretase activity was measured after 2 h of DMSO (solvent control) and CA incubation. Compared to the control, CA at 150 μM decreased
Aβ42 by 50 % (n = 2 per group, repeated 2–3 times). e Aβ spectra obtained from MALDI-TOF mass spectrometry studies show that 20 μM CA
from in vitro study decrease Aβ42 peak and increase Aβ38 peak compared to the DMSO treated control group. f For AICD spectra, AICD49-99
and AICD50-99 are presented as the dominant isoforms in both DMSO control and 20 μM CA treated groups. g-i The effects of CA as a GSM
are shown in primary neuron-glia culture (n = 6). Mouse endogenous Aβ (mAβ) levels were measured by sandwich ELISAs. Cmpd E (γ-secretase
inhibitor) decreased overall Aβ production. GSM-1, an acidic type GSM, was used as a positive control. For the primary neuron-glia culture, GSM-1
at 1 μM decreased level of mAβ42, but increased mAβ38 level. CA at 3 μM and 10 μM presented dose-dependent effects for decreasing mAβ42
and increasing mAβ38. Results were analyzed by two-way analysis of variance (ANOVA) followed by bonferroni post-hoc testing for group differences
(Fig. 1d) and one-way analysis of variance (ANOVA) followed by Dunnett’s multiple comparisons (Fig. 1g-i). (***p < 0.001, **p < 0.01, *p < 0.5)
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mouse postnatal day 0 (P0) neuron-glia cultures of wild-
type mice to determine the effect of CA on endogenous
mouse Aβ (mAβ) levels (Fig. 1g-j). CA decreased mAβ42
production by ~60 % at 3 μM and by ~75 % at 10 μM
(Fig. 1g) and increased Aβ38 production at 10 μM (Fig. 1h)
resulting in a significant decrease in the Aβ42:Aβ38 ratio
at both concentrations (Fig. 1l). Thus, confirming that
CA acts as GSM on primary brain cells.
Loss of Cyp27a1 and Cyp7b1 alters mouse brain Aβ42
To determine whether CA levels could affect Aβ42 pro-
duction in vivo, we assessed Aβ levels in both Cyp27a1+/+,
Cyp27a1+/− and Cyp27a1−/− mice brains and Cyp7b1+/+,
Cyp7b1+/− and Cyp7b1−/− mice brains. In the brain,
Cyp27a1 catalyzes the synthesis of CA from 27-OHC
and Cyp7b1 catabolizes CA (Fig. 2a). From the previ-
ous literature, loss of Cyp27a1 has been shown to eli-
minate the levels of 27-OHC production in the mouse
brain, suggesting decreased CA levels, whereas loss of
Cyp7b1 increases mouse brain CA levels from ~30 nM
to ~300 nM [36]. In humans with loss of function
mutations in CYP27A1 and CYP7B1, there is reduced
and elevated CSF or plasma CA, respectively [36]. For
our studies, mouse brains were harvested at 3 months
and endogenous mouse Aβ levels measured by ELISA.
Fig. 2b shows mAβ42/mAβ40 ratio measured from the
Cyp27a1 mouse brains. There was a significant 23 % in-
crease in the mAβ42/mAβ40 ratio in Cyp27a1−/− mice
compared to Cyp27a1+/+ (Fig. 2b). Because Cyp27a1 mice
were poor breeders, we did not obtain enough animals for
an accurate measurement of brain Aβ38 levels. Con-
versely, Cyp7b1−/− mice showed a significant 21 %
decrease in mAβ42/mAβ40 ratio (Fig. 2c) and a significant
25 % increase in mAβ38/mAβ40 ratio (Fig. 2d) compared
to control Cyp7b1+/+ mice. In all cases, the ratios of
mAβ40/mAβ42 and mAβ38/mAβ40 in heterozygous
Cyp27a1 or Cyp7b1 mice (Cyp27a1+/− or Cyp7b1+/−)
were intermediate between wild type and null animals, al-
though the differences were not statistically significant.
We attempted to observe amyloid plaque pathology in the
context of Cyp7b1 or Cyp27a1 deficiency. Extensive ef-
forts were made to breed APP(KM670/671NL+V717F) CRND8
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Fig. 2 The effects of Cyp27a1 and Cyp7b1 genetic reductions on brain mAβ levels. a CA is found in the acidic cholesterol elimination pathway.
Cholesterol is hydrolyzed by Cyp27a1 to produce 27-hydroxycholesterol (27-OHC) and CA sequentially. CA is further metabolized by Cyp7b1
generating CA derivatives, 7α-hydroxy-cholestenoic acid (7α-OH-CA) and 7α-hydroxy-4-oxo-cholestenoic acid (7α-OH-4-CA). Genetic deletion of
Cyp27a1 is predicted to decrease endogenous CA levels, whereas the deletion of Cyp7b1 is predicted to accumulate CA. b Cyp27a1 (−/−)
increased brain mAβ42/Aβ40 ratio compared to Cyp27a1 (+/+) by ~20 %. c-d Cyp7b1 (−/−) decreased the ratio between mAβ42 to mAβ40 by ~20 %
compared to Cyp7b1 (+/+), whereas increased the ratio of mAβ38/Aβ40 by ~30 %. 6–8 mice were tested in the group. The results were analyzed by
one-way analysis of variance (ANOVA) followed by Dunnett’s multiple comparisons. *p < 0.05
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transgenic mice onto or Cyp7b1−/− genotype, but
these efforts were unsuccessful. Though a few APP+/−
on the Cyp7b1−/− backgrounds were generated, none
of these survived past 3 months of age. Thus, we were
unable to evaluate the effects of loss of Cyp7b1 on
amyloid deposition.
Intraperitoneal injections of CA did not alter mouse brain
Aβ levels
To test the acute effect of CA in vivo, CA (30 mg/kg) or
GSM-1 (30 mg/kg), a potent GSM compound (Fig. 3),
was given to wild type mice, and the brains were har-
vested after 30 min, 1, 2, and 3 h. While the positive
control GSM-1 showed the expected Aβ modulation in
mouse brains after three hours post intraperitoneal (IP)
injection [37], there were no changes in Aβ levels after
CA administration (Fig. 3a-c). It should be noted in
these studies that the half-life (T1/2) for CA in humans
is reported to be 90 min [38]. Next, a dose–response
study was performed with CA given to wild type mice at
30, 60, 75, and 100 mg/kg doses with brains harvested
3 h after dosing. CA was well tolerated in mice up to the
highest concentration (100 mg/kg). The Fig. 3d demon-
strates CA plasma concentrations after injections of
various doses in C57BL/6 mice. The standard curve for
CA measurement showed a linear response with the
limit of quantification of 100 ng/mL (~250 nM), which
is close to physiological plasma CA concentration (100-
300 nM) [39, 36, 40]. When different doses (30, 60, 75,
100 mg/kg) of CA were injected, plasma CA concen-
trations increased in dose dependent manner from
200 ng/mL (~500 nM) at 30 mg/kg dose to 4000 ng/mL
(~10 μM) at 100 kg/mg dose (Fig. 3d). This might indi-
cate some non-linearity in pharmacokinetics of CA. No
significant effects of CA on mAβ42, mAβ38, and total
mAβ compared to the vehicle-injected control were
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Fig. 3 mAβ levels in the brains are measured after intraperitoneal (IP) injections of racemic mixture of CA in C57BL/6 and CF-1 mice (wild-type mice).
At varying doses and time-points, CA did not show acute effects on brain mAβ42, mAβ38, and total mAβ levels. CA was administered at 30 mg/kg,
60 mg/kg, 75 mg/kg and 100 mg/kg and the brains were harvest 30 min after the injections in C57BL/6 or CF-1 mice. In addition, this was performed
in time-course manner at 30 mg/kg. The brains were harvested at different time points (30 min, 1 h, 2 h and 3 h). The representative results of IP
injections of GSM-1 and CA at 30 mg/kg at 1-h time point for mAβ42 (a), mAβ38 (b), and total Aβ (c) are demonstrated by mouse Aβ ELISAs.
Solutol-based vehicle is utilized as a control and 6 mice were tested per group. (d) CA levels in the plasma in the wild type mice (n = 3-6) after IP
injections at multiple doses are demonstrated. With the gradual increase in dosage (30 mg/kg, 60 mg/kg, 75 mg/kg, and 100 mg/kg), the plasma
CA levels have increased. The results were analyzed by one-way analysis of variance (ANOVA) followed by Dunnett’s multiple comparisons.
(***p < 0.001, **p < 0.01)
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observed up to the highest 100 mg/kg dose (data not
shown).
GSM activity of CA analogs
We had previously screened 170 commercially available
steroids and identified 5β-cholanic acid as the most
potent steroid GSM within that set of compounds [26].
5β-Cholanic acid 1 (Fig. 4) decreased Aβ42 with an EC50
of 5.7 μM [26]. In this report, we have identified CA 2a
as a potent GSM with an EC50 of 250 nM for decreasing
Aβ42. As such, 2a was comparable in potency to an op-
timized GSM clinical candidate phenylacetic acid EVP-
0962 3 and to preclinical tool compound GSM-1 4, as
representative reference compounds from the carboxylic
acid chemotype (Fig. 4).
A striking structural feature of CA relative to previ-
ous potent GSMs is the extended C5 alkylene tether
linking the carboxylate group to the lipophilic core
steroid nucleus. To date, potent GSMs such as 3 and
4 have been acetic acids in which the carboxylate group
is linked to a core lipophilic moiety by a single carbon
atom. To evaluate the effects of the alkylene tether, the
structural-activity relationship (SAR) for CA analogs
varying the tether from 3 methylenes to 7 methylenes
(C3-C7) was examined (Table 1). The synthetic chemistry
processes for both 25-(R) and 25-(S) pure diastereomers
of CA, as well as the other CA analogs in Table 1, are
illustrated and detailed in Additional file 1. Shorter tether
analogs 5 (C3 tether analog) and 6 (C4 tether analog)
displayed an order of magnitude lowering of potency
with EC50 values of ~ 2.0 μM. The extended C6 and C7
tether analogs 10 and 11 exhibited a slight decline in
potency (EC50 = 391 nM and 513 nM respectively) rela-
tive to the baseline C5 analog 7.
The SAR around the optimal C5 tether structure
was elucidated with the analogs 2a, 2b, 7, 8 and 9.
The 25-(S)-CA, the methyl group diastereomer 2b,
was about 2-fold less potent than the 25-(R)-CA 2a.
The simple unsubstituted C5 methylene tether analog
7 displaying an EC50 of ~110 nM was more potent
than 2a. The corresponding α,β-unstaturated analog 8
was virtually equipotent to 7. This steroid SAR at the
α-carbon to the carboxylic acid group differs markedly
from the SAR of PAA GSMs such as compound 3
(Fig. 4) where methyl substitution increases potency.
Difluoro analog 9 prepared to favor the putative active
ionized carboxylate, in fact, exhibited an order of mag-
nitude loss in potency relative to the other C5 analogs.
We further explored the SAR of endogenous CA ca-
tabolites found in the acidic pathway (Fig. 5a). 27-OHC,
the precursor of CA, is inactive as a GSM since it is
missing the critical carboxylate group. CA is then con-
verted to 7α-OH-CA and then to 7α-OH-3-CA, there-
fore we tested them for GSM activity in dose dependent
1 5β-cholanic acid
4 GSM-1     Ar=4-CIPh3 EVP-0015962
2a 25(R)-cholestenoic acid
Aβ42 EC50=5700nM Aβ42 EC50=250nM
Aβ42 EC50 CE24βAMn76= 50=92nM
Fig. 4 Chemical structures of acidic steroid type- and phenylacetic acid (PAA) type-GSMs with their EC50 for decreasing Aβ42. 5β-Cholanic acid
(1) has a four-ring structure with a 4-carbon side chain on carbon 17 and its EC50 for decreasing Aβ42 is ~5.7 μM. 25(R)-cholesteonic acid (2a) has
the same four-ring structure with an additional hydroxyl group on carbon 3 and a 6-carbon side chain on carbon 17. For this molecule, the EC50
is at ~250 nM. EVP-0015962 (3), (R)-2-(5-chloro-6-(2,2,2-trifluoroethoxy)-4’-(trifluoromethyl)biphenyl-3-yl)-3-cyclobutylpropanoic acid, shows GSM
activity at EC50 of 67 nM from the previous literature. GSM-1 (4) has the two phenyl rings with the carboxylic acid functional group. The EC50 for
GSM-1 is at 92 nM
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studies (Fig. 5a). Both 7α-OH-CA and 7α-OH-3-CA
demonstrated GSM activity but were not as potent as
CA (Fig. 5a and b). Additionally, we aimed to substitute
fluorine (F) at the carbon 3 and 7 positions of the CA
catabolites as such fluorine substations can block metab-
olism (12–13 in Table 2). Replacement of a 3-OH group
of CA with a 3β-F group could be readily achieved to
give 12 using standard methods. Somewhat surprisingly
this modification in 12 resulted in great reduction in
GSM potency. Attempts to synthesize the 7-F analog of
CA were unsuccessful by routes based on standard
diethylaminosulfur trifluoride (DAST) reaction of a cor-
responding 7-OH intermediate. 7-F delta-5-ene allyl
fluoride steroid compounds could be isolated by DAST
reaction, however these compounds demonstrated in-
stability in our and previous studies [41, 42]. We also
synthesized 3-deoxy-CA 13 based on our previous GSM
SAR findings with cholenic acid analogs [26] and this
demonstrated an EC50 of 670nM, approximately 3-fold
less potent than CA. Collectively, these data demonstrate
that endogenous 2b CA is a relatively optimized steroid-
GSM.
Carboxylic acid tether combined to PAA chemotypes did
not show GSM activities
As phenyl acetic acid (PAA) chemotype GSMs have low
nanomolar potencies for decreasing Aβ42 (Fig. 4, com-
pound 3), we examined whether increasing the length of
the carboxylate tether to the PAA moiety could provide
a path to further potency increases. The structures of
the compounds synthesized are illustrated in Fig. 6a (the
synthesis schemes are provided in Additional file 1). Bi-
phenyl moieties (Fig. 6) were selected because they
showed optimized drug potencies for GSM effects in
previous studies [37, 43, 44]; however, no studies have
been investigated regarding the PAA chemotype GSMs
combined with the extended alkylene tether. Therefore,
we decided to examine whether or not this feature can
enhance potencies. We tested for potential GSM activity
of these compounds by measuring Aβ42 levels at 300nM
and 3 μM (Fig. 6b-c); however, these analogs did not
demonstrate GSM activities at either concentration.
Altogether, these data indicate that the increased po-
tency observed with the C5 carboxylate tether appears
to be specific to the steroid based GSMs and does not
extend to other acid GSM chemotypes.
Table 1 CA analogs EC50 for lowering Aβ42
R1 Cmpd# Aβ42 EC50 (nM)
5 1780
6 1960
7 110
8 148
2a 250
2b 501
9 2193
10 391
Table 1 CA analogs EC50 for lowering Aβ42 (Continued)
11 513
EC50=half maximal effective concentration
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Discussion
In this study, we identified CA as a potent acidic GSM
with an EC50 for lowering Aβ42 of ~250 nM, a concen-
tration well within the normal range of CA levels in hu-
man plasma (~100-300 nM). This data raised the
possibility that CA was an endogenous GSM and that
increasing brain CA levels might be a safe approach to
lower brain Aβ42 levels. Peripheral dosing of CA, how-
ever, did not lower brain Aβ42 despite extremely high CA
levels in the plasma (~10 μM), indicating that either CA
does appear to readily cross the blood brain barrier or, if it
does, is rapidly exported from the brain. Unfortunately,
using our methodology, we were not able to accurately
measure CA levels with sufficient sensitivity to accurately
measure CA levels in the brains of these mice.
Given the potency of CA as a GSM, we explored
whether mice with genetic deletions of Cyp27a1 [33, 34]
and Cyp7b1 [35], the two enzymes regulating CA levels
Table 2 Fluorine and deoxy CA analogs EC50 for lowering Aβ42
R1 R2 Cmpd # Aβ42 EC50 (nM)
β-F α-H 12 8906
β-H β-H 13 671
EC50=half maximal effective concentration
CYP27A1
CYP27A1
CYP7B1
HSD3B7
Cholesterol
27-OHC
CA
A
Aβ42 EC50=NA
Aβ42 EC50=250nM
Aβ42 EC50=970nM
Aβ42 EC50=4150nM
Endogenous CA derivatives
Concentration (nM)
%
D
M
S
O
100 102 104
0
50
100
150
CA
7α-OH-CA
7α-OH-4-CA
27-OHC
B
Fig. 5 CA derivatives produced in the cholesterol elimination pathway decrease Aβ42 levels in CHO-2B7 cells. a Acidic pathway of the cholesterol
elimination pathways is illustrated. Sequential hydroxylation on the carbon-23 by Cyp27a1 converts cholesterol to CA, and then Cyp7b1 converts
CA to a CA derivative, 7α-OH-CA. 7α-OH-CA is further dehydrogenized by HSD3b7 producing 7α-OH-4-CA. b Dose–response curves were established
to determine EC50 for the cholesterol metabolites found in this pathway using the conditioned media from CHO-2B7 cells treated with them.
Compared to the DMSO control, CA and its derivatives showed Aβ decreasing effects at different EC50s. CA EC50 was at 250nM, 7α-OH-CA was at
970nM, and 7α-OH-4-CA was at 4150nM. 27-OHC EC50 could not be determined
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in the brain [31], showed alterations in mAβ42 levels.
We found that the mAβ42/mAβ40 ratio was increased
in the Cyp27a1−/− mice and mAβ42/mAβ40 ratio was
decreased in Cyp7b1−/− mice, where CA levels were
shown to decrease or increase CA levels, respectively
[36]. Given that these shifts in ratio in these knockout
mice are precisely what would be predicted if CA dem-
onstrated GSM activity, we concluded that CA is likely
to be a bona fide endogenous GSM synthesized in a
cholesterol elimination pathway in brain [31]. Given the
challenges of measuring levels of endogenous Aβ outside
of the brain in wild type mice, we attempted to generate
Cyp7b1−/−, APP+/− (CRND8) mice. Despite extensive
efforts, we were unable to generate mice with this geno-
type that lived past 3 months. We did not attempt to
cross the CRND8 mice with Cyp27a1−/− mice, because
Cyp27a1−/− mice were even less fecund than the
Cyp7b1−/− mice. Future studies in humans with genetic
loss of function of CYP27A1 that causes cerebrotendi-
nous xanthomatosis (CTX) [45, 36] or with genetic loss
of function of CYP7B1 deficiency that causes liver failure
in children or spastic paraplegia 5 (SPG5) in adults [46,
39, 36], might help to further establish the likelihood
that CA is an endogenous GSM, as these patients show
altered CA levels and would be predicted to have altered
Aβ42/Aβ40 ratios [39, 36]; however, due to the small
F3C
COOH
F3C
COOH
COOH
O
CF3
COOH
O
CF3
analogs_300nM
DM
SO
UF
-G
SM
1
UF
-G
SM
2
UF
-G
SM
3
UF
-G
SM
4
UF
-G
SM
5
0
50
100
150
Aβ42
Aβ40
analogs_3uM
DM
SO
UF
-G
SM
1
UF
-G
SM
2
UF
-G
SM
3
UF
-G
SM
4
UF
-G
SM
5
0
50
100
150
Aβ42
Aβ40
UF-GSM4
UF-GSM5
A UF-GSM1
UF-GSM2
UF-GSM3
B C
Fig. 6 PAA-extended C5 alkylene tether grafting analogs. a PAA compounds combined with the COOH-tether were synthesized. b-c The treatments
of the grafted compounds did not alter Aβ40 and Aβ42 levels significantly at 300nM or 3 μM concentrations
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number of patients with these rare disorders, and the
severe disease induced by loss of these CYP enzymes,
such studies may be challenging to sufficiently power
and control.
Building off our previous studies to examine a large
number of steroids for GSM and inverse GSM (iGSM)
activity [26], we synthesized a number of analogs to see
if we can further increase potency. From these studies,
we can conclude that CA seems to represent a relatively
optimized steroid GSM, especially the C5 alkene tether
linking the carboxylate group to the steroid backbone
which appears to be optimal in length for maximizing
steroid GSM potency. Indeed, there was a significant
increase in GSM potency upon increasing the tether
length from C3 to C5, but there was only a moderate
loss of potency for increased C6 and C7 tether. Based on
the observations from extended CA tether analogs, we
explored the effects of C5 alkene tether carboxylates on
other acidic GSM “scaffolds”. In all cases examined, this
“grafting” approach decreased potency, indicating that
the positon of the carboxylate group for optimal GSM
potency is dependent on the overall structure of the
molecule. Further modifications along the steroid back-
bone all decreased GSM activity relative to CA. For
example, both endogenous CA metabolites 7α-OH-CA
and 7α-OH-3-CA maintained GSM activity, but were
less potent than CA.
Our findings that CA and other steroids can modify
Aβ production expand the growing number of studies
that demonstrate how cholesterol and other steroids can
modulate Aβ profiles [47–54]. Of particular interest are
studies showing that cholesterol binds to APP CTFβ
[22, 23], albeit with low affinity, as this might suggest
that CA, a cholesterol metabolite, could also interact
with CTFβ. Our studies also show that CA behaves
much like classic acidic GSMs and like all GSMs, exhibit
a fairly flat SAR. Moreover, membrane lipids have been
shown to alter the profile of Aβ produced [55], and
therefore it is theoretically possible that CA could alter
γ-secretase in a similar manner. However, given the
nanomolar potency of CA and the aforementioned flat
SAR, we think that this mechanism of action is unlikely.
As our data show that it is challenging to generate CA
analogs that retain potency, we have not attempted to
generate CA analogs that could be used for affinity studies
to identify primary binding sites. Given the nanomolar po-
tency of CA, we speculate that it almost certainly interacts
with PSEN/γ-secretase. However, as we have previously
hypothesized, we would propose that most GSMs alter γ-
secretase through a complex interaction involving both
substrate and γ-secretase and possibly even other lipid
membrane components [56, 57, 26, 58, 59]. Such a model
is consistent with data showing that GSM effects are
extremely sensitive to mutations within the substrate
[59, 58, 60] and could explain why different GSM affinity
probes have been shown to bind PSEN, PEN2 or C99
[56, 61–63]. It is important to consider that demonstrating
binding with such a probe to a certain component does
not rule out interaction with the other components, due
to limitations where the reactive groups can be placed on
the GSM affinity probes and the requirement for photoaf-
finity probes to have its photoaffinity label be in very close
proximity to the bound protein.
In summary, although the endogenous metabolite CA
is a potent γ-secretase modulator, i) its lack of ability to
lower brain Aβ42 following peripheral dosing and ii) the
inability to identify additional endogenous CA analogs
with increased potency, suggests that pursuing CA or
CA analogs for further preclinical development is not
likely to be fruitful. Recent data show that CA can be
toxic to primary mouse motor neuron in cultures [36]
and raises concerns for pursuing CA or CA derivate as
possible new small molecule therapeutics for AD. As the
immediate precursor of CA, 27-OHC cholesterol, readily
crosses the blood brain barrier, a pro-drug approach
using a modified 27-OHC might be considered as an
alternative strategy; however, emerging data that elevated
27-OHC may be a risk factor for osteoporosis and breast
cancer, raises concerns about a 27-OHC cholesterol
prodrug strategy to increase CA levels as well [64, 65].
Methods
Cell culture and drug treatment
Chinese hamster ovary (CHO) cells stably overexpress-
ing APP695 (CHO-2B7 cells) [66] were grown in Ham’s
F-12 medium (Life Technologies) supplemented with
10 % fetal bovine serum and 100 units/ml of penicillin
and 100 μg/ml streptomycin. Cells were grown at 37 °C
in a humidified atmosphere containing 5 % CO2 in tissue
culture plates (Costar). The cells were harvested at con-
fluence and then utilized for biochemical analyses. Com-
pounds were dissolved in dimethyl sulfoxide (DMSO)
and screened in CHO-2B7 cells. The cells were incu-
bated for 16 h in the presence of the compound diluted
into OptiMEM-reduced serum medium (Life Technolo-
gies, Carlsbad, CA, USA) containing 1 % fetal bovine
serum. Compounds used for our study were either
purchased from Avanti Polar Lipids, Inc. or synthesized
by SAI Life Sciences Ltd. The synthesis schemes of the
newly synthesized compounds are demonstrated in
Additional file 1.
In vitro γ-secretase assay
Broken cell assays were performed with slight modifica-
tions from the previous studies [67, 18]. The membrane
derived from the H4 neuroglioma cells overexpressing
APP695wt were prepared by carbonate extraction and
incubated at 37 °C for 2 h with CA at various
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concentrations. Aβ levels were quantified by sandwich
ELISAs. For Aβ and AICD spectra, the recombinant
C100Flag proteins were overexpressed and purified from
Escherichia coli BL21 using a HiTrap Q-column (GE Life
Science, Little Chalfont, U.K.) [68, 69, 58]. The mem-
brane containing γ-secretase was isolated from the CHO
S-1 cell line using sodium carbonate (100 mM, pH 11.0)
[70]. For the in vitro γ-secretase assay, C100Flag recom-
binant protein at 25 μM was incubated with the mem-
brane (100 μg/mL) in the presence of CA (20 μM) and
DMSO in 150 mM sodium citrate buffer (pH 6.8) con-
taining complete protease inhibitor (Roche, Indianapolis,
IN) for 2 h at 37 °C.
Mice
All procedures were performed according to the
National Institute of Health Guide for the Care and Use
of Experimental Animals and were approved by the
University of Florida Institutional Animal Care and Use
Committee. The Cyp27a1−/− (B6.129-Cyp27a1tm1Elt/J)
and Cyp7b1−/− (B6;129S-Cyp7b1tmRus/J) strains were
obtained from Jackson Laboratory (Bar Harbor, ME).
Cyp27a1−/− mice were bred with C57BL/6 in order to
produce the heterozygous littermates of Cyp27a1, and
Cyp7b1−/− mice were bred with C57BL/6 mice to pro-
duce the heterozygous Cyp7b1 littermates. The wild
type, heterozygous, and knockout littermates of Cyp27a1
and Cyp7b1 mice were generated from Cyp27a1+/− X
Cyp27a1+/− and Cyp7b1+/− X Cyp7b1+/−, respectively.
Primary mixed neuron-glia culture
Primary mixed neuron-glia cultures were prepared from
postnatal day 0 (P0) C3HBL/6 mouse brains (Harlan
Labs). Cerebral cortices were dissected from P0 mouse
brains and were dissociated in 2 mg/ml papain
(Worthington) and 50 μg/mL DNAse I (Sigma) at 37 °C
for 20 min. They were then washed three times in sterile
Hank’s balanced salt solution (HBSS) to inactivate the
papain and switched to 5 % fetal bovine serume
(HyClone) in Neurobasal-A growth media (Gibco),
which includes 0.5 mM L-glutamine (Gibco), 0.5 mM
GlutaMax (Life Technologies), 0.01 % antibiotic-
antimycotic (Gibco), and 0.02 % SM1 supplement (Stem-
cell). The tissue mixture was then triturated three times
using a 5 mL pipette followed by a Pasteur pipette, and
strained through a 70 μm cell strainer. The cell mixture
was then centrifuged at 200xg for 3 min, and re-
suspended in fresh Neurobasal-A media. They were then
plated onto poly-D-lysine coated 96well plates at
100,000 cells/well. Cells were maintained in the
Neurobasal-A growth media mentioned above without
fetal bovine serum (FBS) at 37 °C in a humidified 5 %
CO2 chamber.
CA IP injections
25(R)-CA powder was initially dissolved in DMSO
(<4.5 % in the final mixture) and then combined with
polyethylene glycol (15)-hydroxystearate (Solutol), etha-
nol, and water at a ratio of (15:10:75). One molar equiva-
lent of sodium hydroxide was added to the mixture
[71, 72]. We performed CA intraperitoneal (IP) injec-
tions to wild-type mice (C57BL/6 or CF-1). The mice
were injected with 25(R)-CA on the right side of the ab-
domen. The injections have been performed with various
time points (30 min, 1 h, 2 h, and 3 h) and with multiple
doses (30 mg per kg (mg/kg), 60 mg/kg, 75 mg/kg and
100 mg/kg). The number of each cohort is 6–8. We used
30 mg/kg of CA for the time-course experiments, and
for the dose–response experiments the end-point was
set at 30 min. The brains and serum are harvested and
frozen for brain Aβ extraction.
Brain Aβ extraction
The mouse brains were harvested at the age of 3 months.
The brains were weighed and recorded. The Diethyla-
mine/Sodium Chloride (DEA/NaCl) extraction buffer
(0.4 % DEA) was added to each sample and homoge-
nized using a sonicator. The samples were transferred to
a poly-carbonate centrifuge tube and spun down at
50,000xg for 30 min at 4 °C. The supernatant was loaded
on the vacuum manifold with the appropriate number of
HLB Oasis columns. The samples were loaded on the
conditioned column, filtered, and eluted using prepared
elution buffer (90 % Methanol, 2 % NH4OH). The elu-
ates are concentrated using the Thermo-Savant Speed-
Vac concentrator for a minimum of 2 h at 55 °C with
radiant heat. The concentrated samples are reconstituted
in a blocking buffer (0.67 % Bovine serum albumin
(BSA)) at the appropriate volume.
Plasma CA analysis
The plasma samples were extracted using published
solid phase extraction method (72) and analyzed by
HPLC-MS-MS. Briefly, 0.1 ml mouse plasma samples
after adding 20 μl of D3-CA as internal standard were
preconditioned with 1.4 ml of ethanol (99.9 %), and
0.5 ml of water, centrifuged at 4 °C, 4000 rpm for
10 min. This solution was then loaded onto a Sep-Pak
tC18 (SPE1) solid phase extraction cartridge which were
preconditioned with 70 % ethanol. The sample was
washed with one column volume of 70 % ethanol then
eluted from the column by 2 + 1 ml of 99.9 % ethanol; it
was dried in centrifuge evaporator. The residue was
reconstituted in 100 μl of isopropanol. It was oxidized
by adding 1 ml of 50 mM phosphate buffer (pH = 7)
containing 3 μl of cholesterol oxidase and incubated at
37 °C for 1 h, quenched with 1.9 ml of methanol. The
mixture was further processed by adding 150 μl glacial
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acetic acid and 1 smidgen (about 80 mg) GP reagent
{1-(carboxymethyl) pyridinium chloride hydrazide} and
incubated at room temperature overnight in the dark.
On the next day, a second solid phase extraction [73]
was employed to separate the derivatized CA from the
excess derivatization reagent using the following:
Sep-pak C18 (SPE 2, different from SPE1) cartridge with
1 column volume of 99.9 % methanol and 1 column vol-
ume of 10 % methanol, after application of the sample
wash with 10 % methanol, then elute with 2*1 ml of
100 % methanol. Mix 200 μl of the elution solution with
50 μl of water to obtain 250 μl of 80/20 (methanol/water,
v/v) samples. 20 μl was injected onto HPLC-MS-MS
for analysis.
HPLC-MS-MS conditions: HPLC contains a Perkin
Elmer series 200 autosampler and a Perkin Elmer series
200 pump, MS-MS was Waters Quattro LC-Z, ES
positive mode, Cone voltage 45 volts, collision energy
30volts, Desolvation temperature 350 °C. Source block
temperature 120 °C. MS/MS transitions: CA 549.0/
470.0; D3-CA 552.0/473.0. HPLC mobile phase was 80/
20 Methanol/water(v/v) containing 0.1 %Formic Acid,
HPLC column was ThermoFisher Hypersil Gold,
50*2.1 mm, 1.9 μ, flow rate 0.2 ml/min. Injection volume
20 μl, run time 4 min, CA retention time 1.4 min.
Antibodies and ELISAs
Monoclonal antibodies to Aβ were generated by the
Mayo Clinic Immunology Core facilities (Jacksonville,
FL, USA). Ab5 recognizes an epitope in the amino
terminus of Aβ (Aβ1-16), recognizes both monomeric
and aggregated Aβ, and is human specific. Ab13.1.1. was
raised against Aβ35-40 and is specific for Aβx-40, and
exhibits minimal cross-reactivity with other Aβ peptides.
Ab 2.1.3 was raised against Aβ35-42 and is specific for
Aβx-42. The Aβ38 antibody (Ab38), supplied by P.
Mehta (Institute of Basic Research, Staten Island, NY,
USA), specifically recognizes Aβx-38 and shows no
cross-reactivity with other Aβ peptides [74]. For cell-
based screens, Aβ was captured from conditioned
medium with either Ab5, Ab38, Ab13.1.1, or Ab2.1.3
(coated at 10-50 μg/ml in EC buffer: 5 mM NaH2PO4-
H2O, 20 mM Na2HPO4, 400 mM NaCl, 2.5 mM
EDTA-full name, 151.5 μM BSA, 813 μM CHAPS, and
7.7 mM NaN3) on Immulon 4HBX Flat-Bottom Micro-
filter 96-well plates (Thermo Scientific, Waltham, MA,
USA). Total Aβ level was determined by capture with
Ab5 and detected with horseradish peroxidase (HRP)-
conjugated 4G8 (a monoclonal antibody against Aβ17-
24; Covance, Waltham, MA, USA) with the other Aβ
peptides detected with HRP-conjugated Ab5. For the
cell-free assay and measuring mouse endogenous Aβ,
HRP-conjugated 4G8 was used as the secondary detec-
tion antibody. Aβ standards (Bachem, King of Prussia,
PA, USA) were prepared by dissolving in hexafluoroiso-
propanol (HFIP) at 1 mg/ml with sonication, dried
under nitrogen, resuspended at 2 mg/ml HFIP, sonicated
again and dried under nitrogen. The resulting Aβ was
resuspended in 0.01 % ammonium hydroxide, portioned
into aliquots in EC buffer, and frozen at −80 °C. Follow-
ing these steps, the Aβ is monomeric, as determined by
size-exclusion chromatography.
Immunoprecipitation-Mass spectrometry
Conditioned media from the CHO-2B7 cells and the
samples prepared from in vitro γ-secretase studies were
used to analyze Aβ and AICD profiles using matrix-
assisted laser desorption/ionization time of flight
(MALDI-TOF) mass spectrometry analysis. The secreted
Aβ peptides were analyzed as previously described with
the following modifications [2, 75, 76]. Briefly, the Aβ pep-
tides were immunoprecipitated using Ab5 recognizing
the Aβ1-16 epitope [77] and sheep anti-mouse IgG mag-
netic Dynabeads (Life Technologies, catalog no. 11201D)
and the AICD fragments were captured using anti-Flag
M2 magnetic beads (Sigma). The samples were washed
and eluted with 10 μM solution of 0.1 % trifluoroacetic
acid (TFA) in water. Eluted samples were mixed 2:1 with
saturated α-cyano-4-hydroxycinnamic acid (CHCA)
matrix (Sigma) in acetonitrile: methanol (60:40 %) and
loaded onto a CHCA pretreated MSP 96 target plate-
polished steel (Bruker, Billerica, MA, USA - Part
No.224989). Samples were analyzed using a Bruker
Microflex LRF-MALDI-TOF mass spectrometer.
Statistics
In vitro data were expressed and graphed as the mean ±
SEM using GraphPad Prism 5 software. Analysis was by
one-way analysis of variance (ANOVA) followed by
Dunnett’s multiple comparisons, and was by two-way
analysis of variance (ANOVA) followed by bonferroni
post-hoc testing for group differences. The level of
significance was set at p < 0.05 in all tests.
Additional file
Additional file 1: Schematics of syntheses of (25R)-cholestenoic
acid and its analogs.
Abbreviations
Aβ: Amyloid-β; AD: Alzheimer’s disease; APP: Amyloid precursor protein;
AICD: APP intracellular domain; CTF: APP carboxyl terminal fragment;
CA: Cholestenoic acid; Cyp: Cytochrome P450; CHO: Chinese hamster ovary;
CTX: Cerebrotendinous xanthomatosis; GSM: γ-secretase modulator;
NSAID: Non-steroidal anti-inflammatory drug; SPG5: Spastic paraplegia 5;
SAR: Structure-activity relationship.
Competing interests
The authors declare that they have no competing interests.
Jung et al. Molecular Neurodegeneration  (2015) 10:29 Page 12 of 15
Authors’ contributions
JIJ participated in study design, performed in vitro and cell-based immunoassays,
analyzed data, and drafted manuscript. APR and LAS participated in animal study
design and performed ELISA. TBL and YR performed in vitro and cell-based
assays. HJP and CCD performed primary neuronal culture and ELISA. GH and YT
participated in pharmacokinetics study and performed LC-MS/MS. RA and SB
synthesized CA analogs, which were designed by GS. EHK was involved in
experimental interpretation and manuscript editing. GS, KMF, and TEG
participated in study design and coordination and in manuscript preparation
and editing. All authors read and approved the final manuscript.
Acknowledgements
We thank Patricia Joy for critical reading of this manuscript. This study was
funded in NIH NIA P01 AG020206 grant (EHK and TEG).
Author details
1Center for Translational Research in Neurodegenerative Disease, University
of Florida, Gainesville, FL 32610, USA. 2Department of Neuroscience,
University of Florida, Gainesville, FL 32610, USA. 3McKnight Brain Institute,
College of Medicine, University of Florida, Gainesville, FL 32610, USA.
4College of Pharmacy, University of Florida, Gainesville, FL 32610, USA. 5SAI
Life Sciences Ltd., Turkapally AP500078, India. 6Department of Neuroscience,
University of California, La Jolla, San Diego, CA 92093, USA. 7Pharmore, Inc.,
Gainesville, FL 32653, USA. 8Departments of Medicine and Physiology, Yong
Loo Lin School of Medicine, National University of Singapore, Singapore
119077, Singapore.
Received: 6 April 2015 Accepted: 29 May 2015
References
1. Golde TE, Eckman CB, Younkin SG. Biochemical detection of Aβ isoforms:
implications for pathogenesis, diagnosis, and treatment of Alzheimer’s
disease. Biochim Biophys Acta. 2000;1502(1):172–87. doi:10.1016/s0925-
4439(00)00043-0.
2. Wang R, Sweeney D, Gandy SE, Sisodia SS. The Profile of Soluble Amyloid β
Protein in Cultured Cell Media: detection and quantification of amyloid β
protein and variants by immunoprecipitation-mass spectrometry. J Biol
Chem. 1996;271(50):31894–902.
3. Suzuki N, Cheung TT, Cai XD, Odaka A, Otvos L, Eckman C, et al. An
increased percentage of long amyloid beta protein secreted by familial
amyloid beta protein precursor (beta APP717) mutants. Science
(New York, NY). 1994;264(5163):1336–40.
4. Younkin S. The role of A beta 42 in Alzheimer's disease. J Physiol Paris.
1998;92:289–92.
5. Kim J, Onstead L, Randle S, Price R, Smithson L, Zwizinski C, et al. Aβ40
Inhibits Amyloid Deposition In Vivo. J Neurosci. 2007;27(3):627–33.
doi:10.1523/jneurosci.4849-06.2007.
6. McGowan E, Pickford F, Kim J, Onstead L, Eriksen J, Yu C, et al. Abeta42 is
essential for parenchymal and vascular amyloid deposition in mice. Neuron.
2005;47:191–9.
7. Borchelt DR, Thinakaran G, Eckman CB, Lee MK, Davenport F, Ratovitsky T,
et al. Familial Alzheimer's Disease–Linked Presenilin 1 Variants Elevate
Aβ1–42/1–40 Ratio In Vitro and In Vivo. Neuron. 1996;17(5):1005–13.
doi:http://dx.doi.org/10.1016/S0896-6273(00)80230-5.
8. Duff K, Eckman C, Zehr C, Yu X, Prada C-M, Perez-tur J, et al. Increased
amyloid-[beta]42(43) in brains of mice expressing mutant presenilin 1.
Nature. 1996;383(6602):710–3.
9. Scheuner D. Secreted amyloid β-protein similar to that in the senile plaques
of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and
APP mutations linked to familial Alzheimer's disease. Nat Med. 1996;2:864–70.
doi:10.1038/nm0896-864.
10. Murayama O, Tomita T, Nihonmatsu N, Murayama M, Sun X, Honda T, et al.
Enhancement of amyloid β 42 secretion by 28 different presenilin 1
mutations of familial Alzheimer's disease. Neurosci Lett. 1999;265(1):61–3.
doi:http://dx.doi.org/10.1016/S0304-3940(99)00187-1.
11. Caughey B, Lansbury PT. Protofibrils, pores, fibrils, and neurodegeneration:
Separating the Responsible Protein Aggregates from The Innocent
Bystanders*. Annual Review of Neuroscience. 2003;26(1):267–98.
doi:10.1146/annurev.neuro.26.010302.081142.
12. Wang R, Wang B, He W, Zheng H. Wild-type Presenilin 1 Protects against
Alzheimer Disease Mutation-induced Amyloid Pathology. Journal of
Biological Chemistry. 2006;281(22):15330–6. doi:10.1074/jbc.M512574200.
13. Seubert P, Vigo-Pelfrey C, Esch F, Lee M, Dovey H, Davis D, et al. Isolation
and quantification of soluble Alzheimer's b-peptide from biological fluids.
Nature. 1992;359(6393):325–7.
14. Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y. Visualization
of Aβ42(43) and Aβ40 in senile plaques with end-specific Aβ monoclonals:
Evidence that an initially deposited species is Aβ42(43). Neuron.
1994;13(1):45–53. doi:10.1016/0896-6273(94)90458-8.
15. Gravina SA, Ho L, Eckman CB, Long KE, Otvos L, Younkin LH, et al. Amyloid
β Protein (Aβ) in Alzheimeri's Disease Brain. J Biol Chem. 1995;270(13):7013–6.
doi:10.1074/jbc.270.13.7013.
16. Moore B, Chakrabarty P, Levites Y, Kukar T, Baine A-M, Moroni T, et al.
Overlapping profiles of Abeta peptides in the Alzheimer's disease and
pathological aging brains. Alzheimer's Research & Therapy. 2012;4(3):18.
17. McGowan E, Pickford F, Kim J, Onstead L, Eriksen J, Yu C, et al. Aβ42 Is
Essential for Parenchymal and Vascular Amyloid Deposition in Mice. Neuron.
2005;47(2):191–9. doi:10.1016/j.neuron.2005.06.030.
18. Wahrle S, Das P, Nyborg AC, McLendon C, Shoji M, Kawarabayashi T, et al.
Cholesterol-Dependent γ-Secretase Activity in Buoyant Cholesterol-Rich
Membrane Microdomains. Neurobiol Dis. 2002;9(1):11–23. doi:10.1006/
nbdi.2001.0470.
19. Ehehalt R, Keller P, Haass C, Thiele C, Simons K. Amyloidogenic processing
of the Alzheimer β-amyloid precursor protein depends on lipid rafts. The
Journal of Cell Biology. 2003;160(1):113–23. doi:10.1083/jcb.200207113.
20. Song C, Liao S. Cholestenoic Acid Is a Naturally Occurring Ligand for Liver X
Receptor α. Endocrinology. 2000;141(11):4180–4. doi:10.1210/en.141.11.4180.
21. Golde TE, Eckman CB. Cholesterol modulation as an emerging strategy for
the treatment of Alzheimer's disease. Drug Discovery Today.
2001;6(20):1049–55. doi:10.1016/s1359-6446(01)01965-1.
22. Beel AJ, Sakakura M, Barrett PJ, Sanders CR. Direct binding of cholesterol to
the amyloid precursor protein: An important interaction in lipid–Alzheimer's
disease relationships? Biochimica et Biophysica Acta (BBA) - Molecular and
Cell Biology of Lipids. 2010;1801(8):975–82. doi:10.1016/j.bbalip.2010.03.008.
23. Barrett PJ, Song Y, Van Horn WD, Hustedt EJ, Schafer JM, Hadziselimovic A,
et al. The Amyloid Precursor Protein Has a Flexible Transmembrane Domain
and Binds Cholesterol. Science. 2012;336(6085):1168–71. doi:10.1126/
science.1219988.
24. Grimm MOW, Grimm HS, Tomic I, Beyreuther K, Hartmann T, Bergmann C.
Independent Inhibition of Alzheimer Disease β- and γ-Secretase Cleavage
by Lowered Cholesterol Levels. Journal of Biological Chemistry.
2008;283(17):11302–11. doi:10.1074/jbc.M801520200.
25. Levin-Allerhand JA, Lominska CE, Wang J, Smith JD. 17α-estradiol and
17β-estradiol treatments are effective in lowering cerebral amyloid-β levels
in AβPPSWE transgenic mice. Journal of Alzheimer's Disease.
2002;4(6):449–57.
26. Jung JI, Ladd TB, Kukar T, Price AR, Moore BD, Koo EH, et al. Steroids as
γ-secretase modulators. FASEB J. 2013;27:3775–85. doi:10.1096/fj.12-225649.
27. Kukar T, Golde TE. Possible mechanisms of action of NSAIDs and related
compounds that modulate g-secretase cleavage. Curr Top Med Chem.
2008;8(1):47–53.
28. Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU, et al. A subset of
NSAIDs lower amyloidogenic A[beta]42 independently of cyclooxygenase
activity. Nature. 2001;414(6860):212–6. http://www.nature.com/nature/
journal/v414/n6860/full/414212a0.html.
29. Eriksen JL, Sagi SA, Smith TE, Weggen S, Das P, McLendon DC, et al. NSAIDs
and enantiomers of flurbiprofen target γ-secretase and lower Aβ42 in vivo.
The Journal of Clinical Investigation. 2003;112(3):440–9. doi:10.1172/jci18162.
30. Beel AJ, Sanders CR. Substrate specificity of γ-secretase and other
intramembrane proteases. Cell Mol Life Sci. 2008;65(9):1311–34.
doi:10.1007/s00018-008-7462-2.
31. Meaney S, Heverin M, Panzenboeck U, Ekström L, Axelsson M, Andersson U,
et al. Novel route for elimination of brain oxysterols across the blood–brain
barrier: conversion into 7α-hydroxy-3-oxo-4-cholestenoic acid. Journal of
Lipid Research. 2007;48(4):944–51. doi:10.1194/jlr.M600529-JLR200.
32. Sundaram SS, Bove KE, Lovell MA, Sokol RJ. Mechanisms of Disease: inborn
errors of bile acid synthesis. Nat Clin Pract Gastroenterol Hepatol.
2008;5(8):456–68.
33. Rosen H, Reshef A, Maeda N, Lippoldt A, Shpizen S, Triger L, et al. Markedly
Reduced Bile Acid Synthesis but Maintained Levels of Cholesterol and Vitamin
Jung et al. Molecular Neurodegeneration  (2015) 10:29 Page 13 of 15
D Metabolites in Mice with Disrupted Sterol 27-Hydroxylase Gene. Journal of
Biological Chemistry. 1998;273(24):14805–12. doi:10.1074/jbc.273.24.14805.
34. Honda A, Salen G, Matsuzaki Y, Batta AK, Xu G, Leitersdorf E, et al.
Differences in hepatic levels of intermediates in bile acid biosynthesis
between Cyp27−/− mice and CTX. Journal of Lipid Research.
2001;42(2):291–300.
35. Li-Hawkins J, Lund EG, Turley SD, Russell DW. Disruption of the Oxysterol
7α-Hydroxylase Gene in Mice. Journal of Biological Chemistry.
2000;275(22):16536–42. doi:10.1074/jbc.M001811200.
36. Theofilopoulos S, Griffiths WJ, Crick PJ, Yang S, Meljon A, Ogundare M, et al.
Cholestenoic acids regulate motor neuron survival via liver X receptors. The
Journal of Clinical Investigation. 2014;124(11):4829–42. doi:10.1172/jci68506.
37. Page RM, Baumann K, Tomioka M, Pérez-Revuelta BI, Fukumori A, Jacobsen
H, et al. Generation of Aβ38 and Aβ42 Is Independently and Differentially
Affected by Familial Alzheimer Disease-associated Presenilin Mutations and
γ-Secretase Modulation. J Biol Chem. 2008;283(2):677–83.
doi:10.1074/jbc.M708754200.
38. Babiker A, Andersson O, Lindblom D, van der Linden J, Wiklund B,
Lütjohann D, et al. Elimination of cholesterol as cholestenoic acid in human
lung by sterol 27-hydroxylase: evidence that most of this steroid in the
circulation is of pulmonary origin. Journal of Lipid Research.
1999;40(8):1417–25.
39. Setchell KD, Schwarz M, O'Connell NC, Lund EG, Davis DL, Lathe R, et al.
Identification of a new inborn error in bile acid synthesis: mutation of the
oxysterol 7alpha-hydroxylase gene causes severe neonatal liver disease.
The Journal of Clinical Investigation. 1998;102(9):1690–703.
40. Ogundare M, Theofilopoulos S, Lockhart A, Hall LJ, Arenas E, Sjövall J, et al.
Cerebrospinal Fluid Steroidomics: Are Bioactive Bile Acids Present in Brain?
Journal of Biological Chemistry. 2010;285(7):4666–79. doi:10.1074/
jbc.M109.086678.
41. Khan SN, Kim BJ, Kim H-S. Synthesis and antimicrobial activity of 7-fluoro-3-
aminosteroids. Bioorganic & Medicinal Chemistry Letters. 2007;17(18):5139–42.
doi:http://dx.doi.org/10.1016/j.bmcl.2007.07.001.
42. Marwah P, Thoden JB, Powell DR, Lardy HA. Steroidal allylic fluorination
using diethylaminosulfur trifluoride: A convenient method for the synthesis
of 3β-acetoxy-7α-and 7β-fluoroandrost-5-en-17-one. Steroids.
1996;61(8):453–60. doi:http://dx.doi.org/10.1016/0039-128X(96)00092-X.
43. Imbimbo BP, Del Giudice E, Cenacchi V, Volta R, Villetti G, Facchinetti F, et al.
In vitro and in vivo profiling of CHF5022 and CHF5074: Two β-amyloid1–42
lowering agents. Pharmacological Research. 2007;55(4):318–28.
doi:http://dx.doi.org/10.1016/j.phrs.2006.12.010.
44. Peretto I, Radaelli S, Parini C, Zandi M, Raveglia LF, Dondio G, et al. Synthesis
and Biological Activity of Flurbiprofen Analogues as Selective Inhibitors of
β-Amyloid1-42 Secretion. Journal of Medicinal Chemistry. 2005;48(18):5705–20.
doi:10.1021/jm0502541.
45. Björkhem I, Leitersdorf E. Sterol 27-hydroxylase Deficiency: A Rare Cause of
Xanthomas in Normocholesterolemic Humans. Trends in Endocrinology
&amp; Metabolism. 2000;11(5):180–3. doi:10.1016/s1043-2760(00)00255-1.
46. Lorbek G, Lewinska M, Rozman D. Cytochromes P450 in Synthesis of
Cholesterol and Bile Acids: From Mouse Models to Human Diseases. FEBS
Journal. 2011. doi:10.1111/j.1742-4658.2011.08432.x.
47. Fuller N, Hubbs J, Austin W, Creaser S, McKee T, Loureiro R, et al. The initial
optimization of a new series of gamma-secretase modulators derived from
a triterpene glycoside. ACS Med Chem Lett. 2012;3:908–13.
48. Burg VK, Grimm HS, Rothhaar TL, Grösgen S, Hundsdörfer B, Haupenthal VJ,
et al. Plant Sterols the Better Cholesterol in Alzheimer's Disease? A
Mechanistical Study. The Journal of Neuroscience. 2013;33(41):16072–87.
doi:10.1523/jneurosci.1506-13.2013.
49. Urano Y, Ochiai S, Noguchi N. Suppression of amyloid-β production by 24S-
hydroxycholesterol via inhibition of intracellular amyloid precursor protein
trafficking. The FASEB Journal. 2013;27(10):4305–15. doi:10.1096/fj.13-231456.
50. Irwin RW, Brinton RD. Allopregnanolone as regenerative therapeutic for
Alzheimer's disease: Translational development and clinical promise.
Progress in Neurobiology. 2014;113(0):40–55. doi:http://dx.doi.org/10.1016/
j.pneurobio.2013.08.004.
51. Amtul Z, Wang L, Westaway D, Rozmahel RF. Neuroprotective mechanism
conferred by 17beta-estradiol on the biochemical basis of Alzheimer's
disease. Neuroscience. 2010;169(2):781–6. doi:10.1016/
j.neuroscience.2010.05.031.
52. Sun J-H, Yu J-T, Tan L. The Role of Cholesterol Metabolism in Alzheimer’s
Disease. Mol Neurobiol. 2014:1–19. doi:10.1007/s12035-014-8749-y
53. Popp J, Lewczuk P, Kölsch H, Meichsner S, Maier W, Kornhuber J, et al.
Cholesterol metabolism is associated with soluble amyloid precursor
protein production in Alzheimer's disease. Journal of Neurochemistry.
2012;123(2):310–6. doi:10.1111/j.1471-4159.2012.07893.x.
54. Hubbs J, Fuller N, Austin W, Shen R, Creaser S, McKee T, et al. Optimization
of a natural product-based class of gamma-secretase modulators. J Med
Chem. 2012;55:9270–82.
55. Holmes O, Paturi S, Ye W, Wolfe MS, Selkoe DJ. Effects of Membrane Lipids
on the Activity and Processivity of Purified γ-Secretase. Biochemistry.
2012;51(17):3565–75. doi:10.1021/bi300303g.
56. Kukar TL, Ladd TB, Bann MA, Fraering PC, Narlawar R, Maharvi GM, et al. Substrate-
targeting g-secretase modulators. Nature. 2008;453(7197):925–9. doi:http://
www.nature.com/nature/journal/v453/n7197/suppinfo/nature07055_S1.html.
57. Kukar TL, Ladd TB, Robertson P, Pintchovski SA, Moore B, Bann MA, et al.
Lysine 624 of the Amyloid Precursor Protein (APP) Is a Critical Determinant
of Amyloid β Peptide Length. J Biol Chem. 2011;286(46):39804–12.
doi:10.1074/jbc.M111.274696.
58. Jung JI, Ran Y, Cruz PE, Rosario AM, Ladd TB, Kukar TL, et al. Complex
Relationships between Substrate Sequence and Sensitivity to Alterations in
γ-Secretase Processivity Induced by γ-Secretase Modulators. Biochemistry.
2014;53(12):1947–57. doi:10.1021/bi401521t.
59. Jung JI, Premraj S, Cruz PE, Ladd TB, Kwak Y, Koo EH, et al. Independent
Relationship between Amyloid Precursor Protein (APP) Dimerization and
γ-Secretase Processivity. PLoS ONE. 2014;9(10):e111553. doi:10.1371/
journal.pone.0111553.
60. Sagi SA, Lessard CB, Winden KD, Maruyama H, Koo JC, Weggen S, et al.
Substrate Sequence Influences γ-Secretase Modulator Activity, Role of the
Transmembrane Domain of the Amyloid Precursor Protein. J Biol Chem.
2011;286(46):39794–803. doi:10.1074/jbc.M111.277228.
61. Ohki Y, Higo T, Uemura K, Shimada N, Osawa S, Berezovska O, et al.
Phenylpiperidine-type [gamma]-secretase modulators target the
transmembrane domain 1 of presenilin 1. EMBO J. 2011;30(23):4815–24.
http://emboj.embopress.org/content/30/23/4815.long.
62. Jumpertz T, Rennhack A, Ness J, Baches S, Pietrzik CU, Bulic B, et al.
Presenilin is the molecular target of acidic gamma-secretase modulators in
living cells. PLoS ONE. 2012;7:e30484.
63. Ebke A, Luebbers T, Fukumori A, Shirotani K, Haass C, Baumann K, et al.
Novel γ-Secretase Enzyme Modulators Directly Target Presenilin Protein.
J Biol Chem. 2011;286(43):37181–6. doi:10.1074/jbc.C111.276972.
64. Nelson ER, DuSell CD, Wang X, Howe MK, Evans G, Michalek RD, et al. The
Oxysterol, 27-Hydroxycholesterol, Links Cholesterol Metabolism to Bone
Homeostasis Through Its Actions on the Estrogen and Liver X Receptors.
Endocrinology. 2011;152(12):4691–705. doi:10.1210/en.2011-1298.
65. Nelson ER, Chang C-y, McDonnell DP. Cholesterol and breast cancer
pathophysiology. Trends in Endocrinology & Metabolism. 2014;25(12):649–55.
doi:http://dx.doi.org/10.1016/j.tem.2014.10.001.
66. Murphy MP, Uljon SN, Fraser PE, Fauq A, Lookingbill HA, Findlay KA, et al.
Presenilin 1 regulates pharmacologically distinct g-secretase activities.
Implications for the role of presenilin in g-secretase cleavage. J Biol Chem.
2000;275:26277–84.
67. McLendon C, Xin T, Ziani-Cherif C, Murphy MP, Findlay KA, Lewis PA, et al.
Cell-free assays for g-secretase activity. The FASEB Journal. 2000.
doi:10.1096/fj.00-0286fje.
68. Kimberly WT, Esler WP, Ye W, Ostaszewski BL, Gao J, Diehl T, et al. Notch
and the Amyloid Precursor Protein Are Cleaved by Similar γ-Secretase(s).
Biochemistry. 2003;42(1):137–44. doi:10.1021/bi026888g.
69. Esler WP, Kimberly WT, Ostaszewski BL, Ye W, Diehl TS, Selkoe DJ, et al.
Activity-dependent isolation of the presenilin– γ-secretase complex reveals
nicastrin and a γ substrate. Proc Natl Acad Sci USA. 2002;99(5):2720–5.
doi:10.1073/pnas.052436599.
70. Fraering PC, Ye W, LaVoie MJ, Ostaszewski BL, Selkoe DJ, Wolfe MS. γ-
Secretase Substrate Selectivity Can Be Modulated Directly via Interaction
with a Nucleotide-binding Site. J Biol Chem. 2005;280(51):41987–96.
doi:10.1074/jbc.M501368200.
71. Price AR, Xu G, Siemienski ZB, Smithson LA, Borchelt DR, Golde TE, et al.
Comment on “ApoE-Directed Therapeutics Rapidly Clear β-Amyloid and
Reverse Deficits in AD Mouse Models”. Science. 2013;340(6135):924.
doi:10.1126/science.1234089.
72. Shen Q. Improvement of colchicine oral bioavailability by incorporating
eugenol in the nanoemulsion as an oil excipient and enhancer.
Int J Nanomedicine. 2011;6:1237–43.
Jung et al. Molecular Neurodegeneration  (2015) 10:29 Page 14 of 15
73. Karu K, Hornshaw M, Woffendin G, Bodin K, Hamberg M, Alvelius G, et al.
Liquid chromatography-mass spectrometry utilizing multi-stage
fragmentation for the identification of oxysterols. Journal of Lipid Research.
2007;48(4):976–87. doi:10.1194/jlr.M600497-JLR200.
74. Jung JI, Ladd TB, Kukar T, Price AR, Moore BD, Koo EH, et al. Steroids as
γ-secretase modulators. The FASEB Journal. 2013;27(9):3775–85.
doi:10.1096/fj.12-225649.
75. Kukar T, Murphy MP, Eriksen JL, Sagi SA, Weggen S, Smith TE, et al. Diverse
compounds mimic Alzheimer disease-causing mutations by augmenting
Ab42 production. Nat Med. 2005;11(5):545–50. http://www.nature.com/nm/
journal/v11/n5/full/nm1235.html.
76. Murphy MP, Uljon SN, Fraser PE, Fauq A, Lookingbill HA, Findlay KA, et al.
Presenilin 1 regulates pharmacologically distinct γ-secretase activities:
implications for the role of presenilin in γ-secretase cleavage. J Biol Chem.
2000;275(34):26277–84. doi:10.1074/jbc.M002812200.
77. Levites Y, Das P, Price RW, Rochette MJ, Kostura LA, McGowan EM, et al.
Anti-Aβ42– and anti-Aβ40–specific mAbs attenuate amyloid deposition in
an Alzheimer disease mouse model. J Clin Invest. 2006;116(1):193–201.
doi:10.1172/jci25410.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Jung et al. Molecular Neurodegeneration  (2015) 10:29 Page 15 of 15
